| Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'16 | Sep'16 | Jun'16 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities | |||||||||
Net loss | |||||||||
-21,285 | -17,064 | -16,379 | -19,333 | -19,522 | -19,657 | -13,770 | -7,600 | -7,174 | -12,416 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Research and development-licenses acquired, expensed | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 5,000 |
Non-cash research and development expenses | |||||||||
- | - | - | - | - | - | - | -101 | 6,753 | 6,988 |
Depreciation | |||||||||
31 | 19 | 19 | 13 | 10 | 6 | 3 | - | - | - |
Amortization of debt discount and debt issuance costs | |||||||||
287 | 205 | 233 | 230 | 228 | 188 | 0 | - | - | - |
Stock-based compensation | |||||||||
3,690 | 2,730 | 3,213 | 1,447 | 4,036 | 4,191 | 2,816 | - | - | - |
Other non-cash items | |||||||||
- | -16 | -24 | - | - | 0 | 0 | - | - | - |
Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | |||||||||
-411 | 1,430 | -387 | -2,350 | -447 | 3,409 | 0 | - | - | - |
Inventory | |||||||||
516 | -143 | -80 | 2,609 | 1,218 | 563 | 0 | - | - | - |
Prepaid expenses | |||||||||
1,354 | -396 | -517 | -802 | 698 | 719 | 153 | 27 | -10 | 20 |
Accounts payable | |||||||||
-687 | 2,078 | -313 | 713 | -1,474 | 1,111 | -832 | 144 | -4 | 17 |
Accrued expenses | |||||||||
1,857 | -3,076 | 299 | -1,061 | 5,587 | 4,505 | 1,249 | 7,116 | 38 | 55 |
Accrued interest | |||||||||
53 | 56 | -6 | 4 | -1 | 76 | -1,005 | - | - | - |
Due to related party | |||||||||
-17 | 0 | -18 | 35 | 0 | -4 | -93 | 25 | -313 | 371 |
Other liabilities | |||||||||
- | - | 0 | - | - | - | 44 | - | - | - |
Net cash used in operating activities | |||||||||
-19,440 | -15,927 | -11,944 | -17,409 | -12,605 | -11,911 | -11,741 | -327 | -655 | -5 |
Cash flows from investing activities | |||||||||
Purchases of furniture and equipment | |||||||||
267 | 0 | 19 | 98 | 30 | 110 | 129 | - | - | - |
Net cash used in investing activities | |||||||||
-267 | 0 | -19 | -98 | -30 | -110 | -129 | - | - | - |
Cash flows from financing activities | |||||||||
Payment of note payable | |||||||||
0 | 0 | 0 | 0 | 0 | 0 | 31,077 | - | - | - |
Payment of term loan, including a $0.6 million prepayment fee | |||||||||
0 | 20,600 | 0 | - | 0 | -40 | 40 | - | - | - |
Capital contribution - PBM Capital | |||||||||
- | - | - | - | - | - | - | 0 | 509 | 187 |
Proceeds from exercise of stock options | |||||||||
1,523 | 351 | 100 | 47 | -33 | 80 | 45 | - | - | - |
Proceeds from the issuance of common stock | |||||||||
0 | 0 | 0 | 0 | 0 | 0 | 80,000 | - | - | - |
Payment of offering cost in connection with issuance of common stock | |||||||||
0 | 0 | 0 | - | 0 | 263 | 5,007 | - | - | - |
Net cash provided by financing activities | |||||||||
11,373 | 6 | 100 | 46 | -33 | 19,819 | 43,921 | 19,000 | 10,509 | 187 |
Net change in cash and equivalents | |||||||||
-8,334 | -15,921 | -11,863 | - | -12,668 | 7,798 | 32,051 | - | - | - |
Net increase in cash and equivalents | |||||||||
- | - | - | - | - | - | - | 18,673 | 9,854 | 182 |
Supplemental disclosure of cash flow information: | |||||||||
Cash paid for interest | |||||||||
518 | 304 | 337 | 326 | 319 | 190 | 1,321 | - | - | - |
Supplemental disclosure of noncash investing and financing activities: | |||||||||
Accrued offering costs | |||||||||
- | - | 0 | - | - | - | 265 | - | - | - |
Shares issued from the early exercise of options | |||||||||
0 | 0 | 0 | 0 | 0 | 0 | 100 | - | - | - |
Subscription receivable | |||||||||
- | - | - | - | - | - | - | - | - | 65 |
Capital contribution - PBM Capital Investments, LLC - payment of AkaRx upfront purchase price | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 5,000 |